The Deputy Administrator of the Drug Enforcement Administration (DEA) issued a notice of intent temporarily placing the substance 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), including its optical isomers, salts, and salts of isomers into Schedule I of the Federal Controlled Substances Act (CSA). 2C-T-7 is structurally related to the Schedule I substance 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and it has those structural features of phenethylamines which are necessary for stimulant and/or hallucinogenic activity. There is no approved therapeutic use of 2C-T-7 in the United States, and the safety of this substance has never been demonstrated.

This action was based on the following:

(1) 2,5-dimethoxy-4-(n)-propylthiophenethylamine is structurally and pharmacologically related to other Schedule I hallucinogens;
(2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has no accepted therapeutic use in the United States and is not safe for use under medical supervision; and,
(3) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has a high potential for abuse, similar to other Schedule I phenethylamines.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Chapter 481, Health and Safety Code, at least thirty-one days have expired since notice of the above referenced action was published in the Federal Register, and in my capacity as Commissioner of the Texas Department of Health, I do hereby order that the substance 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers be added to Schedule I of the Texas Controlled Substances Act. Schedule I of said Act is hereby amended to read as follows:

SCHEDULE I

Schedule I consists of:

! Schedule I opiates

* * *

! Schedule I opium derivatives

* * *

! Schedule I hallucinogenic substances

unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific

chemical designation (for the purposes of this Schedule I hallucinogenic substances section only, the term “isomer” includes optical, position, and geometric isomers):

(1) Alpha-ethyltryptamine (some trade or other names: etryptamine; Monase; alpha- ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; AET);

(2) 4-bromo-2,5-dimethoxyamphetamine (some trade or other names: 4-bromo-2,5- dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA);

(3) 4-bromo-2,5-dimethoxyphenethylamine (some trade or other names: Nexus; 2C-B; 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB);

(4) 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

(5) 2,5-dimethoxy-4-ethylamphetamine (some trade or other names: DOET);

*(6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomer, salts and salts of isomers;

(7) 5-methoxy-3,4-methylenedioxy-amphetamine;

(8) 4-methoxyamphetamine (some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; PMA);

(9) 1-methyl-4-phenyl-1,2,5,6-tetrahydro-pyridine (MPTP);

(10) 4-methyl-2,5-dimethoxyamphetamine (some trade and other names: 4-methyl-2,5-dimethoxy-alpha-methyl-phenethylamine; "DOM"; and "STP");

(11) 3,4-methylenedioxy-amphetamine;

(12) 3,4-methylenedioxy-methamphetamine (MDMA, MDM);

(13) 3,4-methylenedioxy-N-ethylamphetamine (some trade or other names: N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine; N-ethyl MDA; MDE; MDEA);

(14) 3,4,5-trimethoxy amphetamine;

(15) N-hydroxy-3,4-methylenedioxyamphetamine (Also known as N-hydroxy MDA);

(16) Bufotenine (some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine);

(17) Diethyltryptamine (some trade and other names: N,N-Diethyltryptamine; DET);

(18) Dimethyltryptamine (some trade and other names: DMT);

(19) Ethylamine Analog of Phencyclidine (some trade or other names: N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl)-ethylamine; cyclohexamine; PCE);

(20) Ibogaine (some trade or other names: 7-Ethyl-6,6-beta, 7,8,9,10,12,13-octhydro-2-methoxy-6,9-methano-5H-pyrido[1',2':1,2]azepino[5,4-b] indole; taber-nanthe iboga);

(21) Lysergic acid diethylamide;

(22) Marihuana;

(23) Mescaline;

(24) N-ethyl-3-piperidyl benzilate;

(25) N-methyl-3-piperidyl benzilate;

(26) Parahexyl (some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl);

(27) Peyote, unless unharvested and growing in its natural state, meaning all parts of the plant classified botanically as *Lophophora*, whether growing or not, the seeds of the plant, an extract from a part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or extracts;

(28) Psilocybin;

(29) Psilocin;

(30) Pyrrolidine analog of phencyclidine (some trade or other names: 1-(1-phenyl-cyclohexyl)-pyrrolidine, PCPy, PHP);

(31) Tetrahydrocannabinols;

(32) Synthetic equivalents of the substances contained in the plant *Cannabis*, or in the resinous extractives of that plant, and synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as: delta-1 cis or trans tetrahydrocannabinol, and their optical isomers; delta-6 cis or trans tetrahydrocannabinol, and their optical isomers; delta-3,4 cis or trans tetrahydrocannabinol, and its optical isomers; (Compounds of these structures, regardless of numerical designation of atomic positions, since nomenclature of these substances is not internationally standardized);

(33) Thiophene analog of phencyclidine (some trade or other names: 1-[1-(2-thienyl)cyclohexyl]-piperidine; 2-thienyl analog of phencyclidine; TPCP); and

(34) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (some trade or other names: TCPy);

! Schedule I stimulants

* * *

! Schedule I depressants

* * *

Changes to the schedules are designated by an asterisk (*)

Done in Austin, Texas this _____day of _____, 2002 in witness whereof I hereunto set my hand and seal of office.

_____

Eduardo J. Sanchez, M.D., M.P.H.
Commissioner of Health